Pfizer believes it has a winner with Eliquis. It has the right market niche, a replacement for blood thinner warfarin, and the clinical data that should make it a star. What it hasn't had so far is a fast start toward bigtime sales.
Bristol-Myers Squibb's first-quarter earnings dropped 44%, on a 27% decline in sales. Fortunately, the $3.83 billion revenue line was only slightly worse than analysts expected, given generic competition for blockbuster heart drugs Avapro and Plavix.
If AstraZeneca decides it needs a big acquisition to get out of the doldrums, it may find itself competing with Bristol-Myers Squibb. The Wall Street Journal reports that Bristol-Myers has been kicking tires around the industry, most recently at Biogen Idec.
What would top Xarelto for Bayer and Johnson & Johnson? Xarelto with an easy antidote.
The U.K.'s cost-effectiveness watchdogs must really like Eliquis. The new blood thinner from Pfizer ($PFE) and Bristol-Myers Squibb ($BMY) won a thumbs-up for stroke prevention.
While FiercePharma 's newsletter went on hiatus over the winter holidays--and industry news slowed to a pace suitable to hibernation-friendly weather--we didn't spend all our time skiing and drinking cocoa. Some certifiably big news broke last week. Here are several holiday highlights.
The FDA has handed Bristol-Myers Squibb and Pfizer a very big approval, giving the OK to their blood thinner Eliquis for use in certain patients with atrial fibrillation.
The FDA saved one of its biggest approvals of the year until the end of 2012. Eliquis, the clot buster from Bristol-Myers Squibb and Pfizer, garnered the agency's stamp for use in certain patients with atrial fibrillation.
Bristol-Myers Squibb and Pfizer, which have yet to get their blood thinner Eliquis approved in the U.S., have gotten a third regulatory nod elsewhere.
The approval comes after the drug developers had been stiff-armed twice by the FDA, which has now set a March 17, 2013 PDUFA date on the therapy.